Sharemaestro Newsreel

How Higher Sales, Lower EPS And New Guidance At McKesson (MCK) Has Changed Its Investment Story

On August 5, 2026, McKesson Corporation reported first-quarter fiscal 2027 results showing sales of US$105.38 billion, higher than a year earlier, while net income and earnings per share from continuing operations declined year-on-year. Alongside these results, McKesson completed a large portion of its long-running …

Noticias de acciones de Gilead Sciences Inc (GILD)

Noticias de acciones de Solventum Corp (SOLV)

Hims & Hers Health (HIMS) Responds To FTC Lawsuit Over Patient Data Use

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Hims & Hers Health (NYSE:HIMS) has issued a public response to a Federal Trade Commission lawsuit that challenges aspects of its telehealth practices …

Noticias de acciones de Bionano Genomics Inc (BNGO)

Ginkgo Bioworks Q2 Earnings Call Highlights

Key Points Interested in Ginkgo Bioworks Holdings, Inc.? Here are five stocks we like better. Revenue fell sharply: Second-quarter 2026 revenue declined 48% year over year to $20 million, while net loss widened to $57 million and cash burn increased to $45 million. Ginkgo …

Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Revenue: $5 billion, up 4.4% on an FX-neutral basis. Adjusted Operating Margin: 24.9%, down 130 basis points versus the prior year. Adjusted Gross Margin: 54.3%, down 100 basis points versus the prior year. Adjusted EPS: $3.23, up 4.9%. …

Moderna (MRNA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth …

Medtronic (MDT) Wins Expanded CE Mark For Affera System In Ventricular Arrhythmias

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Medtronic (NYSE:MDT) receives expanded CE Mark indication for its Affera Mapping and Ablation System and Sphere-9 Catheter for ventricular arrhythmia treatment. The Sphere-9 catheter …

Thermo Fisher Stock Clawed Back From a 31% Slide. A Guidance Raise May Explain Why.

BioNTech (BNTX) Brings In New CEO As Europe Clears Updated COVID 19 Shot

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BioNTech (NasdaqGS:BNTX) named Dr. Guido Oelkers as incoming CEO, marking a major leadership transition …

The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?

Quick Read A blended portfolio made up of two-thirds dividend growth at 3.5% and one-third income at 6% generates $56,000 annually from $1.25M, beating the 4% rule without touching principal. Dividend growers like JNJ and AMGN raising payouts at 6% annually double retirement income …

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from …

Johnson & Johnson EVP forminard sells $4.09m in stock

Hims & Hers Health (HIMS) Launches AI Weight Loss Care, Is It Still A Bargain?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Hims & Hers Health (HIMS) just introduced an AI powered care experience for Hers weight loss members, including a connected smart scale and app …

Humana (HUM) Is Up 5.8% After Cutting 2026 EPS Outlook Amid Strong Q2 And Buybacks

In late July 2026, Humana reported higher second-quarter revenue of US$40,867 million and net income of US$694 million, while also confirming completion of a US$276.13 million share repurchase program initiated in February 2024 and announcing two new board appointments, Paul Smith and Frederick Crawford. …

Noticias de acciones de Cooper Companies Inc (COO)

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., August 07, 2026--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced today that it granted restricted stock unit awards (RSUs) representing an aggregate of 21,556 shares of the Company's common stock and stock option awards to purchase an aggregate of 18,172 shares of the Company's …

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …

Análisis y previsión de acciones de Johnson & Johnson (JNJ)

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, …

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …

Noticias de acciones de IDEXX Laboratories Inc (IDXX)

Noticias de acciones de Beam Therapeutics Inc (BEAM)

Noticias de acciones de Boston Scientific Corp (BSX)

Noticias de acciones de Sarepta Therapeutics Inc (SRPT)

Roche Stock Jumps as Morgan Stanley Sees Drug Breakout

This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …

Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …

What Do Boston Scientific (BSX) Recalls Mean For Device Safety And Clinical Use?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access sheaths due to labeling discrepancies and air …

Noticias de acciones de Elevance Health Inc (ELV)

HIMS & HERS HEALTH INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Hims & Hers Health, Inc. on Behalf of Hims & Hers Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Hims & Hers and would like to discuss your legal …

Noticias de acciones de Fulgent Genetics Inc (FLGT)

Noticias de acciones de Globus Medical Inc (GMED)

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

DENTSPLY SIRONA Inc. XRAY reported second-quarter 2026 adjusted earnings per share (EPS) of 52 cents, down 1.6% year over year on an actual-value basis. The bottom line beat the Zacks Consensus Estimate of 36 cents by 44.4%. GAAP EPS in the quarter was 18 …

CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong

Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due …

Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results?

Cardinal Health CAH is scheduled to report fourth-quarter fiscal 2027 results on Aug. 11, before market open. The Zacks Consensus Estimate for sales is pegged at $65.61 billion, implying 9.1% year-over-year growth. The bottom line estimate is pinned at $2.42, suggesting growth of 16.4%. …